Escape from immunotherapy: possible mechanisms that influence tumor regression/progression.
about
Up-regulation of HLA class-I antigen expression and antigen-specific CTL response in cervical cancer cells by the demethylating agent hydralazine and the histone deacetylase inhibitor valproic acidA generic RNA-pulsed dendritic cell vaccine strategy for renal cell carcinoma.T-cell mediated anti-tumor immunity after photodynamic therapy: why does it not always work and how can we improve it?A new therapy for highly effective tumor eradication using HVJ-E combined with chemotherapy.FOXP3+ Tregs and B7-H1+/PD-1+ T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients: Implication for immunotherapy.An alphavirus vector overcomes the presence of neutralizing antibodies and elevated numbers of Tregs to induce immune responses in humans with advanced cancerPhotodynamic therapy and anti-tumour immunity.The preparation of HL-60 cells vaccine expressing BCG heat shock protein 70 and detection of its immunogenicity in vitro.A novel HLA-B18 restricted CD8+ T cell epitope is efficiently cross-presented by dendritic cells from soluble tumor antigen.GM-CSF gene-modifed cancer cell immunotherapies: of mice and men.Cancer-related symptom clusters, eosinophils, and survival in hepatobiliary cancer: an exploratory study.InCVAX--a novel strategy for treatment of late-stage, metastatic cancers through photoimmunotherapy induced tumor-specific immunityMolecular Mechanism and Potential Targets for Blocking HPV-Induced Lesion DevelopmentSafety and immunologic correlates of Melanoma GVAX, a GM-CSF secreting allogeneic melanoma cell vaccine administered in the adjuvant settingTargeted agents for the treatment of metastatic melanoma.Immunological Characterization of Whole Tumour Lysate-Loaded Dendritic Cells for Cancer Immunotherapy.Pivotal Advance: eosinophil infiltration of solid tumors is an early and persistent inflammatory host response.Preparing clinical grade Ag-specific T cells for adoptive immunotherapy trials.Targeting tumours by adoptive transfer of immune cells.Increased frequency of suppressive regulatory T cells and T cell-mediated antigen loss results in murine melanoma recurrenceAntigen loss and tumor-mediated immunosuppression facilitate tumor recurrenceReview article: immune suppression and colorectal cancer.Potential therapeutic role of natural killer cells in cancer.Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines.Applications of Hemagglutinating Virus of Japan in therapeutic delivery systems.Tissue vaccines for cancer.Loss of S100 antigenicity in metastatic melanoma.A novel phosphorylated STAT3 inhibitor enhances T cell cytotoxicity against melanoma through inhibition of regulatory T cells.nab-Paclitaxel as a potential partner with checkpoint inhibitors in solid tumors.Escape from IFN-γ-dependent immunosurveillance in tumorigenesis.TGF-beta signalling and immunity in prostate tumourigenesis.Cancer immunotherapy: a paradigm shift for prostate cancer treatment.Enhancing photodynamyc therapy efficacy by combination therapy: dated, current and oncoming strategiesImmune-epithelial crosstalk at the intestinal surface.Manipulation of regulatory T cells and antigen-specific cytotoxic T lymphocyte-based tumour immunotherapy.Cancer immunotherapy: nanodelivery approaches for immune cell targeting and trackingDecitabine: a promising epi-immunotherapeutic agent in solid tumors.Manufacture of T cells using the Sleeping Beauty system to enforce expression of a CD19-specific chimeric antigen receptor.Innovative Technologies in Nanomedicines: From Passive Targeting to Active Targeting/From Controlled Pharmacokinetics to Controlled Intracellular Pharmacokinetics.Vγ9Vδ2 T cells and zoledronate mediate antitumor activity in an orthotopic mouse model of human chondrosarcoma.
P2860
Q24288944-B95C5B18-1ACE-4C1A-BA21-42968CFB91E3Q24814644-76C31F44-055E-4FD3-B180-6D15BC00B9D2Q27335110-FF5767CE-DBE4-4497-8EA1-F7F98AA0B9ACQ33299767-18E34E62-380F-48B2-9479-B40009003171Q33320890-B5BCB409-92B6-4233-8658-AAAF1064F841Q34090155-33F4F891-AAB9-40D9-B660-3FC32F0A192BQ34105703-9932A11B-C822-4F66-BD3F-C5899D48C8B2Q34380874-80503F52-6AEE-46B0-8EF6-51A48521CE10Q34412732-5B290318-A0E7-44BD-9FB6-500D52C0FD6AQ34591128-7DFCF83B-41C9-4966-AE12-9B34BA24B706Q35079351-A41BFAC3-EDD6-47D0-A5E9-42DC55975BC7Q35108944-604BE88E-3931-4ABF-A204-736405A2C960Q35636308-346A6353-FC79-4883-8F0B-EACE37FE6837Q35816845-41EFA746-720F-4938-8D75-E67860F79CAAQ35822194-C81C71D3-A41F-434B-9575-9FACB29ABF70Q35900294-33E31628-8A32-4254-A3A8-0887152528DFQ36394033-8AAEBFB5-4BF5-446B-8A93-4EEF4F5A0B60Q36453570-BFB2117F-FA49-41EF-9CB7-089FCD52AF48Q36478870-E7ED8F33-1E93-4634-AD10-DD9FF7F1A064Q36555546-9A535655-9F12-4824-8372-979C4EA448A5Q36570359-38D9C77F-1E7F-4DB7-AC66-54B48C75F572Q36609898-EC202BA0-CC05-4529-B8AE-A6029DF5A949Q36675436-5CF9B84F-CA55-4B13-B0A7-CAAA5BF32C20Q36787548-25A8C30D-9C3F-460B-BD30-94A3E4FE2FACQ37076376-3C620A4E-F684-4163-B2EC-6B27D93BBECAQ37123446-61745911-D8E3-40D6-866D-2B21620C0D07Q37129939-F5747EF0-1815-4556-937D-DF7C250EF491Q37172697-F374F508-0B66-4584-88EE-F1351D91575DQ37536367-436B6D09-3F94-4F24-8A49-40CFC5D3B1D1Q37618482-D9874EB6-1194-4971-858D-726C2C958651Q37670250-B67862D5-5DC5-4772-9314-772036FC44A8Q38013964-923095F6-D7B9-4ABF-AD67-BC4F51E53C0BQ38161363-24FE54EE-9693-41B1-B3C3-60B12BFAFE4BQ38182446-1018858A-CF29-4A5F-B567-8E6E337DB155Q38253084-60A37F2F-4C4A-43B9-A518-62F191BDEC32Q38288055-358998D0-247E-4C34-9CD7-E214EB58F7B2Q38314204-2DAD731D-5ED9-4C84-8953-7256BF9A83F2Q38319552-E352BA42-0E0F-49FA-A66A-6D3F7E25E672Q38802167-B269B2C8-8B52-41AA-8BDB-85FA2530ED93Q38811197-2110F803-A203-452A-AF79-C3D47418AD03
P2860
Escape from immunotherapy: possible mechanisms that influence tumor regression/progression.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Escape from immunotherapy: pos ...... tumor regression/progression.
@ast
Escape from immunotherapy: pos ...... tumor regression/progression.
@en
type
label
Escape from immunotherapy: pos ...... tumor regression/progression.
@ast
Escape from immunotherapy: pos ...... tumor regression/progression.
@en
prefLabel
Escape from immunotherapy: pos ...... tumor regression/progression.
@ast
Escape from immunotherapy: pos ...... tumor regression/progression.
@en
P1476
Escape from immunotherapy: pos ...... e tumor regression/progression
@en
P2093
Robert C Rees
Selman A Ali
P2888
P304
P356
10.1007/S00262-004-0540-X
P577
2004-06-10T00:00:00Z